Technetium-99m (Tc-99m) is a metastable nuclear isomer of technetium-99, a synthetic element with a significant application in nuclear medicine. Discovered in the 1930s by Emilio Segrè and Carlo Perrier, technetium was the first artificially produced element. Tc-99m, in particular, has become the most widely used radioisotope for medical imaging due to its favourable physical and radiological properties.
The primary reason behind Tc-99m widespread use in medical diagnostics is its ideal half-life of approximately six hours. This relatively short half-life allows for the rapid decay and elimination of the radioisotope from the patient’s body, minimizing radiation exposure. Additionally, Tc-99m emits gamma rays with an energy of 140 keV, which is optimal for detection by gamma cameras and single-photon emission computed tomography (SPECT) scanners. These properties enable physicians to obtain high-quality images while ensuring patient safety.
Technetium-99m is typically produced by irradiating a molybdenum-98 (Mo-98) target in a nuclear reactor, which then undergoes a nuclear reaction to form molybdenum-99 (Mo-99). Mo-99 decays to Tc-99m with a half-life of 66 hours, making it a practical generator-produced radioisotope. The Tc-99m is extracted from the Mo-99 through a straightforward chemical process, often called a ‘molybdenum cow’ or ‘technetium generator.’ The on-demand production of Tc-99m from Mo-99 allows healthcare facilities to continuously supply the radioisotope for diagnostic procedures.
One of the major advantages of Tc-99m is its ability to be complexed with various radiopharmaceuticals, allowing it to target specific organs or tissues in the body. For instance, Tc-99m can be combined with methylene diphosphonate (MDP) to assess bone metabolism or with diethylenetriaminepentaacetic acid (DTPA) for renal imaging. These radiopharmaceuticals facilitate the accumulation of Tc-99m in the desired tissue or organ, providing essential diagnostic information through gamma-ray detection.
Tc-99m is crucial in diagnosing various diseases and conditions, including cancer, heart disease, bone disorders, and thyroid issues. Some common imaging techniques using Tc-99m include SPECT, planar imaging, and SPECT/CT. These imaging modalities enable physicians to study the structure and function of organs, identify abnormalities, and monitor the progress of treatments.
You are here:
home »
Technetium-99m, discovered in 1937, transformed medical imaging with its versatile and safe diagnostic applications.
Technetium-99m Radiopharmaceuticals in Advanced Medical Imaging Read Post »
Technetium-99m sulfur colloid provides critical diagnostics for liver, spleen, and bone marrow using targeted nuclear imaging.
The Role of Technetium-99m Sulfur Colloid in Diagnostic Imaging Read Post »
Technetium-99m Sestamibi revolutionises cardiac care by precisely mapping blood flow in diagnosing coronary artery disease.
Technescan, utilising Technetium-99m oxidronate, revolutionises bone imaging by highlighting metabolic activity with high sensitivity and precision.
Technetium-99m Oxidronate (Technescan HDP) for Bone Imaging Read Post »
Technetium-99m medronate is vital in nuclear medicine for precise bone imaging and detecting osteogenesis abnormalities.
Technetium-99m Medronate (MDP-25): Bone Imaging and Osteogenesis Evaluation Read Post »
Tc-99m MAA is pivotal in hepatobiliary imaging, providing crucial functional insights into liver and gallbladder health.
Technetium-99m exametazime (Ceretec) is a pivotal radiopharmaceutical in nuclear medicine, revolutionising brain imaging with high precision and reliability.
Technetium-99m bicisate (Neurolite) facilitates stroke diagnosis by enabling cerebral perfusion imaging, aiding in locating affected brain regions.
Bone imaging is an essential diagnostic tool for detecting bone diseases, injuries, and disorders.
Nuclear Medicine Techniques for Bone Imaging and Cancer Diagnosis Read Post »
